Revolutionary solution for spinal surgeries launched

TheraCell Inc, a leading allograft solution company, announced that its newest procedure-specific fiber graft form, the TheraFuze DBF Fiber Bag, is now available for use in spinal and orthopedic surgeries, including minimally invasive procedures. Additionally, the company announced that a patent related to the Fiber Bag was issued by the United States Patent and Trademark Office last year.

The TheraFuze DBF Fiber Bag is a 100% allograft tissue alternative to the resorbable polymer mesh bag products that are currently on the market. The Fiber Bag is made from cortical demineralized bone fibers and processed using TheraCell’s proprietary Bone Textile™ technology. TheraCell’s patented TheraFuze DBF processes have been developed to produce uniform fiber geometry, size and texture, and to preserve the natural collagen structure of the allograft. TheraCell’s FiberLok™ technology allows the Fiber Bag products to maintain their form and integrity after rehydration, permitting adequate time for manipulation and implantation.

This next generation posterolateral solution is designed to be an improved alternative to the traditional boat, offering complete containment of added graft material. The Fiber Bag may be packed with autograft or additional allograft material, and the open end of the bag can be sutured for closure following rehydration. The fully contained fiber bag construct may be placed in the posterolateral gutters, in a bone void or cavity, or may be delivered using minimally invasive techniques.